0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Psychiatric Long-acting Injection Market Research Report 2026
Published Date: 2026-04-10
|
Report Code: QYRE-Auto-21X17121
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Psychiatric Long acting Injection Market Research Report 2024
BUY CHAPTERS

Global Psychiatric Long-acting Injection Market Research Report 2026

Code: QYRE-Auto-21X17121
Report
2026-04-10
Pages:124
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Psychiatric Long-acting Injection Market

The global Psychiatric Long-acting Injection market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Psychiatric Long-acting Injection competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The North American market for Psychiatric Long-acting Injection is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Psychiatric Long-acting Injection is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Psychiatric Long-acting Injection include Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., Lundbeck, Eli Lilly, Alkermes, Par Pharmaceutical, AbbVie, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Psychiatric Long-acting Injection market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Psychiatric Long-acting Injection. The Psychiatric Long-acting Injection market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Psychiatric Long-acting Injection market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Psychiatric Long-acting Injection manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Psychiatric Long-acting Injection Market Report

Report Metric Details
Report Name Psychiatric Long-acting Injection Market
Segment by Type
  • Aripiprazole Long-acting Injection
  • Haloperidol Long-acting Injection
  • Paliperidone Long-acting Injection
  • Risperidone Long-acting Injection
  • Olanzapine Long-acting Injection
  • Others
by Application
  • Schizophrenia
  • Bipolar Disorder
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., Lundbeck, Eli Lilly, Alkermes, Par Pharmaceutical, AbbVie, Luye Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Psychiatric Long-acting Injection manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Psychiatric Long-acting Injection sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Psychiatric Long-acting Injection Market report?

Ans: The main players in the Psychiatric Long-acting Injection Market are Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., Lundbeck, Eli Lilly, Alkermes, Par Pharmaceutical, AbbVie, Luye Pharmaceutical

What are the Application segmentation covered in the Psychiatric Long-acting Injection Market report?

Ans: The Applications covered in the Psychiatric Long-acting Injection Market report are Schizophrenia, Bipolar Disorder, Others

What are the Type segmentation covered in the Psychiatric Long-acting Injection Market report?

Ans: The Types covered in the Psychiatric Long-acting Injection Market report are Aripiprazole Long-acting Injection, Haloperidol Long-acting Injection, Paliperidone Long-acting Injection, Risperidone Long-acting Injection, Olanzapine Long-acting Injection, Others

1 Psychiatric Long-acting Injection Market Overview
1.1 Product Definition
1.2 Psychiatric Long-acting Injection by Type
1.2.1 Global Psychiatric Long-acting Injection Market Value by Type: 2025 vs 2032
1.2.2 Aripiprazole Long-acting Injection
1.2.3 Haloperidol Long-acting Injection
1.2.4 Paliperidone Long-acting Injection
1.2.5 Risperidone Long-acting Injection
1.2.6 Olanzapine Long-acting Injection
1.2.7 Others
1.3 Psychiatric Long-acting Injection by Application
1.3.1 Global Psychiatric Long-acting Injection Market Value by Application: 2025 vs 2032
1.3.2 Schizophrenia
1.3.3 Bipolar Disorder
1.3.4 Others
1.4 Global Psychiatric Long-acting Injection Market Size Estimates and Forecasts
1.4.1 Global Psychiatric Long-acting Injection Revenue 2021–2032
1.4.2 Global Psychiatric Long-acting Injection Sales 2021–2032
1.4.3 Global Psychiatric Long-acting Injection Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Psychiatric Long-acting Injection Market Competition by Manufacturers
2.1 Global Psychiatric Long-acting Injection Sales Market Share by Manufacturers (2021–2026)
2.2 Global Psychiatric Long-acting Injection Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Psychiatric Long-acting Injection Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Psychiatric Long-acting Injection, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Psychiatric Long-acting Injection, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Psychiatric Long-acting Injection, Product Types and Applications
2.7 Global Key Manufacturers of Psychiatric Long-acting Injection, Date of Entry into the Industry
2.8 Global Psychiatric Long-acting Injection Market Competitive Situation and Trends
2.8.1 Global Psychiatric Long-acting Injection Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Psychiatric Long-acting Injection Players Market Share by Revenue
2.8.3 Global Psychiatric Long-acting Injection Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Psychiatric Long-acting Injection Market Scenario by Region
3.1 Global Psychiatric Long-acting Injection Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Psychiatric Long-acting Injection Sales by Region: 2021–2032
3.2.1 Global Psychiatric Long-acting Injection Sales by Region: 2021–2026
3.2.2 Global Psychiatric Long-acting Injection Sales by Region: 2027–2032
3.3 Global Psychiatric Long-acting Injection Revenue by Region: 2021–2032
3.3.1 Global Psychiatric Long-acting Injection Revenue by Region: 2021–2026
3.3.2 Global Psychiatric Long-acting Injection Revenue by Region: 2027–2032
3.4 North America Psychiatric Long-acting Injection Market Facts & Figures by Country
3.4.1 North America Psychiatric Long-acting Injection Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Psychiatric Long-acting Injection Sales by Country (2021–2032)
3.4.3 North America Psychiatric Long-acting Injection Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Psychiatric Long-acting Injection Market Facts & Figures by Country
3.5.1 Europe Psychiatric Long-acting Injection Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Psychiatric Long-acting Injection Sales by Country (2021–2032)
3.5.3 Europe Psychiatric Long-acting Injection Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Psychiatric Long-acting Injection Market Facts & Figures by Region
3.6.1 Asia Pacific Psychiatric Long-acting Injection Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Psychiatric Long-acting Injection Sales by Region (2021–2032)
3.6.3 Asia Pacific Psychiatric Long-acting Injection Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Psychiatric Long-acting Injection Market Facts & Figures by Country
3.7.1 Latin America Psychiatric Long-acting Injection Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Psychiatric Long-acting Injection Sales by Country (2021–2032)
3.7.3 Latin America Psychiatric Long-acting Injection Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Psychiatric Long-acting Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Psychiatric Long-acting Injection Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Psychiatric Long-acting Injection Sales by Country (2021–2032)
3.8.3 Middle East and Africa Psychiatric Long-acting Injection Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Psychiatric Long-acting Injection Sales by Type (2021–2032)
4.1.1 Global Psychiatric Long-acting Injection Sales by Type (2021–2026)
4.1.2 Global Psychiatric Long-acting Injection Sales by Type (2027–2032)
4.1.3 Global Psychiatric Long-acting Injection Sales Market Share by Type (2021–2032)
4.2 Global Psychiatric Long-acting Injection Revenue by Type (2021–2032)
4.2.1 Global Psychiatric Long-acting Injection Revenue by Type (2021–2026)
4.2.2 Global Psychiatric Long-acting Injection Revenue by Type (2027–2032)
4.2.3 Global Psychiatric Long-acting Injection Revenue Market Share by Type (2021–2032)
4.3 Global Psychiatric Long-acting Injection Price by Type (2021–2032)
5 Segment by Application
5.1 Global Psychiatric Long-acting Injection Sales by Application (2021–2032)
5.1.1 Global Psychiatric Long-acting Injection Sales by Application (2021–2026)
5.1.2 Global Psychiatric Long-acting Injection Sales by Application (2027–2032)
5.1.3 Global Psychiatric Long-acting Injection Sales Market Share by Application (2021–2032)
5.2 Global Psychiatric Long-acting Injection Revenue by Application (2021–2032)
5.2.1 Global Psychiatric Long-acting Injection Revenue by Application (2021–2026)
5.2.2 Global Psychiatric Long-acting Injection Revenue by Application (2027–2032)
5.2.3 Global Psychiatric Long-acting Injection Revenue Market Share by Application (2021–2032)
5.3 Global Psychiatric Long-acting Injection Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Oakwood Labs
6.1.1 Oakwood Labs Company Information
6.1.2 Oakwood Labs Description and Business Overview
6.1.3 Oakwood Labs Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Oakwood Labs Psychiatric Long-acting Injection Product Portfolio
6.1.5 Oakwood Labs Recent Developments/Updates
6.2 Teva
6.2.1 Teva Company Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Teva Psychiatric Long-acting Injection Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 MedinCell
6.3.1 MedinCell Company Information
6.3.2 MedinCell Description and Business Overview
6.3.3 MedinCell Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 MedinCell Psychiatric Long-acting Injection Product Portfolio
6.3.5 MedinCell Recent Developments/Updates
6.4 Janssen
6.4.1 Janssen Company Information
6.4.2 Janssen Description and Business Overview
6.4.3 Janssen Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Janssen Psychiatric Long-acting Injection Product Portfolio
6.4.5 Janssen Recent Developments/Updates
6.5 Otsuka America Pharmaceutical, Inc.
6.5.1 Otsuka America Pharmaceutical, Inc. Company Information
6.5.2 Otsuka America Pharmaceutical, Inc. Description and Business Overview
6.5.3 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Product Portfolio
6.5.5 Otsuka America Pharmaceutical, Inc. Recent Developments/Updates
6.6 Lundbeck
6.6.1 Lundbeck Company Information
6.6.2 Lundbeck Description and Business Overview
6.6.3 Lundbeck Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Lundbeck Psychiatric Long-acting Injection Product Portfolio
6.6.5 Lundbeck Recent Developments/Updates
6.7 Eli Lilly
6.7.1 Eli Lilly Company Information
6.7.2 Eli Lilly Description and Business Overview
6.7.3 Eli Lilly Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Eli Lilly Psychiatric Long-acting Injection Product Portfolio
6.7.5 Eli Lilly Recent Developments/Updates
6.8 Alkermes
6.8.1 Alkermes Company Information
6.8.2 Alkermes Description and Business Overview
6.8.3 Alkermes Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Alkermes Psychiatric Long-acting Injection Product Portfolio
6.8.5 Alkermes Recent Developments/Updates
6.9 Par Pharmaceutical
6.9.1 Par Pharmaceutical Company Information
6.9.2 Par Pharmaceutical Description and Business Overview
6.9.3 Par Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Par Pharmaceutical Psychiatric Long-acting Injection Product Portfolio
6.9.5 Par Pharmaceutical Recent Developments/Updates
6.10 AbbVie
6.10.1 AbbVie Company Information
6.10.2 AbbVie Description and Business Overview
6.10.3 AbbVie Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 AbbVie Psychiatric Long-acting Injection Product Portfolio
6.10.5 AbbVie Recent Developments/Updates
6.11 Luye Pharmaceutical
6.11.1 Luye Pharmaceutical Company Information
6.11.2 Luye Pharmaceutical Description and Business Overview
6.11.3 Luye Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Luye Pharmaceutical Psychiatric Long-acting Injection Product Portfolio
6.11.5 Luye Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Psychiatric Long-acting Injection Industry Chain Analysis
7.2 Psychiatric Long-acting Injection Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Psychiatric Long-acting Injection Production Mode & Process Analysis
7.4 Psychiatric Long-acting Injection Sales and Marketing
7.4.1 Psychiatric Long-acting Injection Sales Channels
7.4.2 Psychiatric Long-acting Injection Distributors
7.5 Psychiatric Long-acting Injection Customer Analysis
8 Psychiatric Long-acting Injection Market Dynamics
8.1 Psychiatric Long-acting Injection Industry Trends
8.2 Psychiatric Long-acting Injection Market Drivers
8.3 Psychiatric Long-acting Injection Market Challenges
8.4 Psychiatric Long-acting Injection Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Psychiatric Long-acting Injection Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Psychiatric Long-acting Injection Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Psychiatric Long-acting Injection Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Psychiatric Long-acting Injection Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Psychiatric Long-acting Injection Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Psychiatric Long-acting Injection Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Psychiatric Long-acting Injection Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Psychiatric Long-acting Injection, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Psychiatric Long-acting Injection, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Psychiatric Long-acting Injection, Product Types and Applications
 Table 12. Global Key Manufacturers of Psychiatric Long-acting Injection, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Psychiatric Long-acting Injection Companies by Tier (Tier 1, Tier 2, Tier 3), based on Psychiatric Long-acting Injection Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Psychiatric Long-acting Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Psychiatric Long-acting Injection Sales by Region (K Units), 2021–2026
 Table 18. Global Psychiatric Long-acting Injection Sales Market Share by Region (2021–2026)
 Table 19. Global Psychiatric Long-acting Injection Sales by Region (K Units), 2027–2032
 Table 20. Global Psychiatric Long-acting Injection Sales Market Share by Region (2027–2032)
 Table 21. Global Psychiatric Long-acting Injection Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Psychiatric Long-acting Injection Revenue Market Share by Region (2021–2026)
 Table 23. Global Psychiatric Long-acting Injection Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Psychiatric Long-acting Injection Revenue Market Share by Region (2027–2032)
 Table 25. North America Psychiatric Long-acting Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Psychiatric Long-acting Injection Sales by Country (K Units), 2021–2026
 Table 27. North America Psychiatric Long-acting Injection Sales by Country (K Units), 2027–2032
 Table 28. North America Psychiatric Long-acting Injection Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Psychiatric Long-acting Injection Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Psychiatric Long-acting Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Psychiatric Long-acting Injection Sales by Country (K Units), 2021–2026
 Table 32. Europe Psychiatric Long-acting Injection Sales by Country (K Units), 2027–2032
 Table 33. Europe Psychiatric Long-acting Injection Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Psychiatric Long-acting Injection Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Psychiatric Long-acting Injection Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Psychiatric Long-acting Injection Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Psychiatric Long-acting Injection Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Psychiatric Long-acting Injection Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Psychiatric Long-acting Injection Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Psychiatric Long-acting Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Psychiatric Long-acting Injection Sales by Country (K Units), 2021–2026
 Table 42. Latin America Psychiatric Long-acting Injection Sales by Country (K Units), 2027–2032
 Table 43. Latin America Psychiatric Long-acting Injection Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Psychiatric Long-acting Injection Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Psychiatric Long-acting Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Psychiatric Long-acting Injection Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Psychiatric Long-acting Injection Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Psychiatric Long-acting Injection Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Psychiatric Long-acting Injection Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Psychiatric Long-acting Injection Sales (K Units) by Type (2021–2026)
 Table 51. Global Psychiatric Long-acting Injection Sales (K Units) by Type (2027–2032)
 Table 52. Global Psychiatric Long-acting Injection Sales Market Share by Type (2021–2026)
 Table 53. Global Psychiatric Long-acting Injection Sales Market Share by Type (2027–2032)
 Table 54. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Psychiatric Long-acting Injection Revenue Market Share by Type (2021–2026)
 Table 57. Global Psychiatric Long-acting Injection Revenue Market Share by Type (2027–2032)
 Table 58. Global Psychiatric Long-acting Injection Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Psychiatric Long-acting Injection Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Psychiatric Long-acting Injection Sales (K Units) by Application (2021–2026)
 Table 61. Global Psychiatric Long-acting Injection Sales (K Units) by Application (2027–2032)
 Table 62. Global Psychiatric Long-acting Injection Sales Market Share by Application (2021–2026)
 Table 63. Global Psychiatric Long-acting Injection Sales Market Share by Application (2027–2032)
 Table 64. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Psychiatric Long-acting Injection Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Psychiatric Long-acting Injection Revenue Market Share by Application (2021–2026)
 Table 67. Global Psychiatric Long-acting Injection Revenue Market Share by Application (2027–2032)
 Table 68. Global Psychiatric Long-acting Injection Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Psychiatric Long-acting Injection Price (US$/Unit) by Application (2027–2032)
 Table 70. Oakwood Labs Company Information
 Table 71. Oakwood Labs Description and Business Overview
 Table 72. Oakwood Labs Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Oakwood Labs Psychiatric Long-acting Injection Product
 Table 74. Oakwood Labs Recent Developments/Updates
 Table 75. Teva Company Information
 Table 76. Teva Description and Business Overview
 Table 77. Teva Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Teva Psychiatric Long-acting Injection Product
 Table 79. Teva Recent Developments/Updates
 Table 80. MedinCell Company Information
 Table 81. MedinCell Description and Business Overview
 Table 82. MedinCell Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. MedinCell Psychiatric Long-acting Injection Product
 Table 84. MedinCell Recent Developments/Updates
 Table 85. Janssen Company Information
 Table 86. Janssen Description and Business Overview
 Table 87. Janssen Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Janssen Psychiatric Long-acting Injection Product
 Table 89. Janssen Recent Developments/Updates
 Table 90. Otsuka America Pharmaceutical, Inc. Company Information
 Table 91. Otsuka America Pharmaceutical, Inc. Description and Business Overview
 Table 92. Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Product
 Table 94. Otsuka America Pharmaceutical, Inc. Recent Developments/Updates
 Table 95. Lundbeck Company Information
 Table 96. Lundbeck Description and Business Overview
 Table 97. Lundbeck Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Lundbeck Psychiatric Long-acting Injection Product
 Table 99. Lundbeck Recent Developments/Updates
 Table 100. Eli Lilly Company Information
 Table 101. Eli Lilly Description and Business Overview
 Table 102. Eli Lilly Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Eli Lilly Psychiatric Long-acting Injection Product
 Table 104. Eli Lilly Recent Developments/Updates
 Table 105. Alkermes Company Information
 Table 106. Alkermes Description and Business Overview
 Table 107. Alkermes Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Alkermes Psychiatric Long-acting Injection Product
 Table 109. Alkermes Recent Developments/Updates
 Table 110. Par Pharmaceutical Company Information
 Table 111. Par Pharmaceutical Description and Business Overview
 Table 112. Par Pharmaceutical Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Par Pharmaceutical Psychiatric Long-acting Injection Product
 Table 114. Par Pharmaceutical Recent Developments/Updates
 Table 115. AbbVie Company Information
 Table 116. AbbVie Description and Business Overview
 Table 117. AbbVie Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. AbbVie Psychiatric Long-acting Injection Product
 Table 119. AbbVie Recent Developments/Updates
 Table 120. Luye Pharmaceutical Company Information
 Table 121. Luye Pharmaceutical Description and Business Overview
 Table 122. Luye Pharmaceutical Psychiatric Long-acting Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. Luye Pharmaceutical Psychiatric Long-acting Injection Product
 Table 124. Luye Pharmaceutical Recent Developments/Updates
 Table 125. Key Raw Materials Lists
 Table 126. Raw Materials Key Suppliers Lists
 Table 127. Psychiatric Long-acting Injection Distributors List
 Table 128. Psychiatric Long-acting Injection Customers List
 Table 129. Psychiatric Long-acting Injection Market Trends
 Table 130. Psychiatric Long-acting Injection Market Drivers
 Table 131. Psychiatric Long-acting Injection Market Challenges
 Table 132. Psychiatric Long-acting Injection Market Restraints
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Psychiatric Long-acting Injection
 Figure 2. Global Psychiatric Long-acting Injection Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Psychiatric Long-acting Injection Market Share by Type: 2025 & 2032
 Figure 4. Aripiprazole Long-acting Injection Product Picture
 Figure 5. Haloperidol Long-acting Injection Product Picture
 Figure 6. Paliperidone Long-acting Injection Product Picture
 Figure 7. Risperidone Long-acting Injection Product Picture
 Figure 8. Olanzapine Long-acting Injection Product Picture
 Figure 9. Others Product Picture
 Figure 10. Global Psychiatric Long-acting Injection Market Value by Application (US$ Million), 2021–2032
 Figure 11. Global Psychiatric Long-acting Injection Market Share by Application: 2025 & 2032
 Figure 12. Schizophrenia
 Figure 13. Bipolar Disorder
 Figure 14. Others
 Figure 15. Global Psychiatric Long-acting Injection Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 16. Global Psychiatric Long-acting Injection Market Size (US$ Million), 2021–2032
 Figure 17. Global Psychiatric Long-acting Injection Sales (K Units), 2021–2032
 Figure 18. Global Psychiatric Long-acting Injection Average Price (US$/Unit), 2021–2032
 Figure 19. Psychiatric Long-acting Injection Report Years Considered
 Figure 20. Psychiatric Long-acting Injection Sales Share by Manufacturers in 2025
 Figure 21. Global Psychiatric Long-acting Injection Revenue Share by Manufacturers in 2025
 Figure 22. Top 5 and Top 10 Global Psychiatric Long-acting Injection Players: Market Share by Revenue in Psychiatric Long-acting Injection in 2025
 Figure 23. Psychiatric Long-acting Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 24. Global Psychiatric Long-acting Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 25. North America Psychiatric Long-acting Injection Sales Market Share by Country (2021–2032)
 Figure 26. North America Psychiatric Long-acting Injection Revenue Market Share by Country (2021–2032)
 Figure 27. United States Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. Canada Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. Europe Psychiatric Long-acting Injection Sales Market Share by Country (2021–2032)
 Figure 30. Europe Psychiatric Long-acting Injection Revenue Market Share by Country (2021–2032)
 Figure 31. Germany Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. France Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. U.K. Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Italy Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Russia Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Asia Pacific Psychiatric Long-acting Injection Sales Market Share by Region (2021–2032)
 Figure 37. Asia Pacific Psychiatric Long-acting Injection Revenue Market Share by Region (2021–2032)
 Figure 38. China Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Japan Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. South Korea Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. India Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Australia Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. China Taiwan Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Southeast Asia Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Latin America Psychiatric Long-acting Injection Sales Market Share by Country (2021–2032)
 Figure 46. Latin America Psychiatric Long-acting Injection Revenue Market Share by Country (2021–2032)
 Figure 47. Mexico Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Brazil Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Argentina Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Colombia Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Middle East and Africa Psychiatric Long-acting Injection Sales Market Share by Country (2021–2032)
 Figure 52. Middle East and Africa Psychiatric Long-acting Injection Revenue Market Share by Country (2021–2032)
 Figure 53. Turkey Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Saudi Arabia Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. UAE Psychiatric Long-acting Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. Global Sales Market Share of Psychiatric Long-acting Injection by Type (2021–2032)
 Figure 57. Global Revenue Market Share of Psychiatric Long-acting Injection by Type (2021–2032)
 Figure 58. Global Psychiatric Long-acting Injection Price (US$/Unit) by Type (2021–2032)
 Figure 59. Global Sales Market Share of Psychiatric Long-acting Injection by Application (2021–2032)
 Figure 60. Global Revenue Market Share of Psychiatric Long-acting Injection by Application (2021–2032)
 Figure 61. Global Psychiatric Long-acting Injection Price (US$/Unit) by Application (2021–2032)
 Figure 62. Psychiatric Long-acting Injection Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS